Zeidner JF, Sallman DA, Recher C, Daver NG, et al. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408.
PMID: 40009500